Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Electromed ( (ELMD) ) has provided an announcement.
At the annual meeting held on November 14, 2025, Electromed, Inc. shareholders elected eight directors for a one-year term. Additionally, they ratified the appointment of RSM US LLP as the independent public accounting firm for the fiscal year ending June 30, 2026, and approved executive compensation on a non-binding basis. The board decided to continue annual votes on executive compensation.
The most recent analyst rating on (ELMD) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Electromed stock, see the ELMD Stock Forecast page.
Spark’s Take on ELMD Stock
According to Spark, TipRanks’ AI Analyst, ELMD is a Outperform.
Electromed’s strong financial performance and positive earnings call are the most significant factors contributing to its score. The technical analysis supports a bullish trend, although the valuation suggests the stock may be overvalued. The absence of a dividend yield is a minor drawback. Overall, Electromed is well-positioned within the medical devices industry with potential for continued growth.
To see Spark’s full report on ELMD stock, click here.
More about Electromed
Electromed, Inc. operates in the medical device industry, focusing on the development and sale of products designed to improve respiratory health.
Average Trading Volume: 65,239
Technical Sentiment Signal: Strong Buy
Current Market Cap: $210.8M
See more data about ELMD stock on TipRanks’ Stock Analysis page.